Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BIORNASDAQ:CELCNASDAQ:DMTKNASDAQ:MDXH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIORBiora Therapeutics$0.60+0.5%$0.98$0.59▼$6.70$21.63M1.09446,963 shs91,155 shsCELCCelcuity$17.01+3.8%$17.55$8.39▼$22.19$517.96M0.78214,627 shs164,391 shsDMTKDermTech$0.66+11.9%$0.87$0.59▼$4.36$22.89M2.52321,489 shs570,476 shsMDXHMDxHealth$2.24-2.2%$2.99$2.15▼$4.64N/AN/A80,038 shs27,085 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIORBiora Therapeutics-6.63%-14.95%-49.62%-34.27%-77.80%CELCCelcuity-3.64%-16.76%-8.94%+11.04%+62.28%DMTKDermTech-0.17%-10.99%-13.99%-53.10%-86.63%MDXHMDxHealth-0.43%-1.72%-9.84%-38.27%-93.14%Strange new buyer driving up gold (Ad)One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."But there's a much better move you can make to get in front of these big moves today.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIORBiora Therapeutics0.8222 of 5 stars0.03.00.00.03.12.50.6CELCCelcuity2.7454 of 5 stars3.53.00.00.02.64.20.0DMTKDermTech0.8136 of 5 stars3.01.00.00.01.60.01.3MDXHMDxHealth2.1723 of 5 stars3.55.00.00.00.60.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIORBiora Therapeutics3.00BuyN/AN/ACELCCelcuity3.00Buy$29.0070.49% UpsideDMTKDermTech2.50Moderate Buy$2.38259.39% UpsideMDXHMDxHealth3.00Buy$28.331,164.88% UpsideCurrent Analyst RatingsLatest CELC, DMTK, MDXH, and BIOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/19/2024DMTKDermTechLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$0.634/19/2024DMTKDermTechStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$1.504/19/2024DMTKDermTechBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral4/12/2024CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.003/28/2024CELCCelcuityCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $25.003/28/2024CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $24.003/28/2024CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.003/7/2024MDXHMDxHealthWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/7/2024MDXHMDxHealthBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.003/7/2024MDXHMDxHealthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$6.00 ➝ $7.003/5/2024DMTKDermTechStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$2.50 ➝ $1.50(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIORBiora TherapeuticsN/AN/AN/AN/A($3.73) per shareN/ACELCCelcuityN/AN/AN/AN/A$5.48 per shareN/ADMTKDermTech$15.30M1.50N/AN/A$1.67 per share0.40MDXHMDxHealth$70.19MN/AN/AN/A$5.97 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIORBiora Therapeutics-$124.11M-$8.57N/AN/AN/AN/AN/A-147.40%5/20/2024 (Estimated)CELCCelcuity-$63.78M-$2.69N/AN/AN/AN/A-54.74%-39.13%5/20/2024 (Estimated)DMTKDermTech-$100.89M-$3.14N/AN/AN/A-659.57%-123.96%-67.94%5/2/2024 (Estimated)MDXHMDxHealth-$43.10MN/A0.00N/AN/AN/AN/AN/A6/5/2024 (Estimated)Latest CELC, DMTK, MDXH, and BIOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023BIORBiora Therapeutics-$0.60-$0.63-$0.03-$0.64N/AN/A3/6/2024Q4 2023MDXHMDxHealthN/A-$0.39-$0.39-$0.39N/A$19.40 million 2/29/2024Q4 2023DMTKDermTech-$0.54-$0.56-$0.02-$0.56$4.05 million$3.92 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIORBiora TherapeuticsN/AN/AN/AN/AN/ACELCCelcuityN/AN/AN/AN/AN/ADMTKDermTechN/AN/AN/AN/AN/AMDXHMDxHealthN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIORBiora TherapeuticsN/A0.300.30CELCCelcuity0.2613.4313.43DMTKDermTechN/A4.594.52MDXHMDxHealthN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIORBiora Therapeutics43.74%CELCCelcuity63.33%DMTKDermTech20.45%MDXHMDxHealthN/AInsider OwnershipCompanyInsider OwnershipBIORBiora Therapeutics23.18%CELCCelcuity24.29%DMTKDermTech5.10%MDXHMDxHealth1.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBIORBiora Therapeutics5835.88 million27.57 millionOptionableCELCCelcuity5530.45 million23.06 millionOptionableDMTKDermTech20634.62 million32.86 millionOptionableMDXHMDxHealth252N/AN/ANot OptionableCELC, DMTK, MDXH, and BIOR HeadlinesSourceHeadlineNotice convening the Annual General Meeting in BioPorto A/Sfinance.yahoo.com - April 4 at 10:52 AM360Dx Top 30 Rises 3 Percent in March360dx.com - April 1 at 12:23 PMMdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offeringglobenewswire.com - March 12 at 4:00 PMAnalysts Conflicted on These Healthcare Names: MDxHealth (MDXH), OrthoPediatrics (KIDS) and Karuna Therapeutics (KRTX)markets.businessinsider.com - March 11 at 9:22 PMMDxHealth Q4 Revenues Rise 50 Percent360dx.com - March 7 at 3:05 PMBuy Rating Affirmed for MDxHealth Amid Strong Q4 Performance and Positive Future Outlookmarkets.businessinsider.com - March 7 at 10:04 AMMdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Resultsglobenewswire.com - March 6 at 4:00 PMMDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6finance.yahoo.com - February 21 at 7:26 PMMDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6finance.yahoo.com - February 21 at 7:26 PMMDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6globenewswire.com - February 21 at 5:00 PMMdxhealth Announces Resignation of Board Memberglobenewswire.com - February 16 at 8:45 AM360Dx Top 30 Slides 1 Percent in January360dx.com - January 31 at 10:00 PMMDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 ...smdailyjournal.com - January 8 at 5:21 PMMDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidancefinance.yahoo.com - January 8 at 5:21 PMMDxHealth Announces Completion of Transition to Single Listing on Nasdaqfinance.yahoo.com - December 18 at 8:36 AMMdxhealth Share Price (MDXH.BR)lse.co.uk - November 15 at 8:31 PMMDxHealth to rise 1,000%, also to stay the same - yes, it’s complicateddhakatribune.com - November 14 at 8:26 AMMDxHealth Completes Reverse Stock Splitocbj.com - November 13 at 8:14 PMMDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rightsfinance.yahoo.com - November 13 at 8:14 PMMDxHealth SA GAAP EPS of -$0.04, revenue of $19.35M beats by $1.05Mmsn.com - November 8 at 7:05 PMMDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023finance.yahoo.com - November 8 at 7:05 PMMDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidationfinance.yahoo.com - November 6 at 8:33 AMMDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8finance.yahoo.com - October 25 at 9:04 PMMDxHealth SA Sponsored ADR (MDXH) Expected to Beat Earnings Estimates: Should You Buy?finance.yahoo.com - October 19 at 12:34 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiora TherapeuticsNASDAQ:BIORBiora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.CelcuityNASDAQ:CELCCelcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.DermTechNASDAQ:DMTKDermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.MDxHealthNASDAQ:MDXHMDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.